Clinical Trial Update: Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating fosaprepitant for prevention of chemotherapy-induced vomiting in patients with advanced non-small cell lung cancer treated wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• FOSAPREPITANT (FOSAPREPITANT DIMEGLUMINE)

Snippet

Sponsor: Ajeet Gajra | Conditions: Non-small Cell Lung Cancer, Vomiting | Phase 2 | Status: UNKNOWN